Cell Reprogramming Market: Industry Trends and Global Forecasts - Distribution by Type of Technology, Type of Source Cell, Type of Application and Key Geographical Regions

List of Tables

GLOBAL CELL REPROGRAMMING MARKET: OVERVIEW

As per Roots Analysis, the global cell reprogramming market valued at USD 1.16 billion in the current year is anticipated to grow at a CAGR of 8% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Technology

Sendai Virus-based Reprogramming
mRNA Reprogramming
Episomal Reprogramming
Other Reprogramming Technologies

Type of Source Cell

Fibroblasts
Peripheral Blood Mononuclear Cells
Unspecified Somatic Cells
Other Cells

Type of Application

Research
Therapeutic

Key Geographical Regions

North America
Europe
Asia-Pacific and Rest of the World

GLOBAL CELL REPROGRAMMING MARKET: GROWTH AND TRENDS

Progress in stem cell biology and regenerative medicine over the years has led to the discovery and development of various stem cell-based therapies. However, prevalent challenges concerning the development and use of cell therapies persist, including complex production process, scarcity of healthy cell donors, and concerns associated with donor-recipient haplotype mismatch. Moreover, there are still several ethical barriers when it comes to using human stem cells for research purposes. Consequently, the concept of cell reprogramming has emerged as one of the means to overcome the aforementioned issues and develop safe and effective cell-based therapeutic interventions.

Empowered by technical developments in the field of biotechnology and the market opportunity associated with regenerative medicine, a number of research groups across the world are presently developing innovative ways to reprogram cells. Further, it is worth noting that various start-ups and university spin-offs have emerged as pioneers in this emerging field of therapeutics and are anticipated to maintain the research momentum in the coming years as well.

GLOBAL CELL REPROGRAMMING MARKET: KEY INSIGHTS

The report delves into the current state of global cell reprogramming market and identifies potential growth opportunities within industry. Some key findings from the report include:

Advances in cell reprogramming have paved way for a plethora of advanced therapeutic and research applications, resulting in lucrative business opportunities for industry and non-industry service provider firms.
More than 30 companies claim to offer cell reprogramming services and products. Of these, close to 70% are small firms (having less than 50 employees).
Presently, the majority (~75%) of the service providers claim to offer iPSC generation services, using episomal reprogramming technologies, and are capable of working with various types of cells. This is followed by the companies offering direct reprogramming services (30%).
It is worth mentioning that majority of stakeholders claim to be using episomal reprogramming for generating iPSCs; other popular cell reprograming approaches include Sendai virus and mRNA-based technologies.
Numerous companies claim to use more than two technologies for the generation of iPSCs; examples include Applied StemCell, Applied Biological Materials, Creative Bioarray, Lonza and Stemnovate.
Given the various advantages associated with fibroblasts, such as easy availability, faster proliferation rate and cell robustness, these cells have found maximum (>40%) usage in cell reprogramming.
Featuring the presence of several small and mid-sized firms, the cell reprogramming landscape is well distributed across various regions; players have established multiple facilities to cater to the needs of their clients.
North America is a key services hub for cell reprogramming. More than 55% of companies engaged in cell reprogramming are headquartered in North America. This is followed by players based in Europe (45%).

Prominent facilities within Europe include the UK, Germany, Denmark, Switzerland, France, Portugal and Sweden. Stakeholders are actively expanding their capabilities in order to enhance their respective cell reprogramming service portfolios and, thereby, maintain a competitive edge in this upcoming industry.
The rising interest in this field is reflected in the number of partnerships, involving a varied range of cell types, inked in the recent past; the maximum partnering activity has been observed in the US.
Since 2016, the partnership activity has increased at a CAGR of 7%; with the increasing demand for stem cells, both industry and academic players are likely to enter into multiple alliances for cell reprogramming.
Both established players and new entrants have forged several strategic partnerships in the recent past; majority (>30%) of the deals have primarily been inked for generations of iPSCs, which are further differentiated based on the client's requirement.
A number of companies have signed multiple deals for cell reprogramming; examples of the firms that have signed over four deals include Cellaria, BlueRock Therapeutics, FUJIFILM Cellular Dynamics and STEMCELL Technologies.
In the last few years, over 540 clinical trials, evaluating various types of stem cell therapies have been initiated; this highlights the rising demand for iPSC generation and direct reprogramming strategies.
>70% of these trials were / are being sponsored by small / mid-sized companies to exploit the potential of stem cell therapies to cater to the unmet need in this domain.
An evaluation of more than 300+ stakeholders engaged in the development of stem cell therapies reveals several likely strategic partners for cell reprogramming service providers, across different geographical regions.
The market is anticipated to grow at a CAGR of 8% till 2030, and the opportunity is likely to be distributed across different types of technologies, applications and key geographical regions.

Presently, the majority share of service revenues is generated from projects involving episomal reprogramming technologies.
In 2030, episomal reprogramming focused projects are anticipated to contribute over 40% of the overall share; it is expected to be followed by revenues generated from projects involving Sendai virus-based reprogramming (30%) and mRNA (25%).

Example Players in the Cell Reprogramming Market

Allele Biotechnology
ALSTEM
Applied Biological Materials
Axol Bioscience
Creative Bioarray
DefiniGEN
FUJIFILM Cellular Dynamics
Lonza
Mogrify
REPROCELL
Stemnovate
Thermo Fisher Scientific

GLOBAL CELL REPROGRAMMING MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global cell reprogramming market, focusing on key market segments, including [A] type of technology, [B] type of source cell, [C] type of application and [D] key geographical regions.
Market Landscape: A comprehensive evaluation of cell reprogramming market, considering various parameters, such as [A] year of establishment, [B] company size, [C] geographical location, [D] location of manufacturing facilities, [E] type of service, [F] type of offering, [G] type of technology, [H] type of vector used, [I] source cell for iPSC generation, [J] target indication(s), [K] type of application and [L] additional service(s) offered.
Company Competitiveness Analysis: A comprehensive company competitive analysis of iPSC generation and direct reprogramming service providers, examining factors, such as [A] supplier strength and [B] service strength.
Company Profiles: In-depth profiles of the players that offer cell reprogramming services and products, focusing on [A] company overview, [B] financial information (if available), [C] details on cell reprogramming approaches, [D] types of cell(s) utilized and differentiated, [E] target indication(s), [F] other drug discovery services offered and [G] recent developments and an informed future outlook.
Clinical Trial Analysis: An insightful analysis more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, based on several parameters, such as [A] trial registration year, [B] phase of development, [C] study design, [D] current trial status, [E] leading industry sponsors, [F] study focus, [G] type of stem cells, [H] target indication(s), [I] target therapeutic area(s), [J] enrolled patient population and [K] regional distribution of trials.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the cell reprogramming market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of stem cell, [D] target therapeutic area, [E] application, [F] most active players (in terms of the number of partnerships signed) and [G] geography.
Likely Partnership Opportunities: A detailed discussion on the stem cell therapy developers / manufacturers that are anticipated to partner with cell reprogramming service and product providers in the foreseen future, based on various relevant parameters, such as [A] company size, [B] type of cell (s), [C] indication counts and [D] existing partnership(s).

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100193

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of Stem Cells
- 3.2.1. Classification of Stem Cells
  - 3.2.1.1. Based on Source of Stem Cell
  - 3.2.1.2. Based on Origin of Stem Cell
  - 3.2.1.3. Based on Potency of Stem Cell
- 3.2.2. Routes of Administration of Stem Cell Therapies
- 3.2.3. Applications of Stem Cell Therapies
3.3. Introduction to Cell Reprogramming
- 3.3.1. Cell Reprogramming Approaches and Affiliated Technologies
3.4. Applications of Cell Reprogramming
3.5. Key Growth Drivers and Constraints

4. CURRENT MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Cell Reprogramming Service and Product Providers: List of Industry Players
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Geographical Location
- 4.2.4. Analysis by Location of Stem Cell Research Facilities
- 4.2.5. Analysis by Type of Service
- 4.2.6. Analysis by Type of Technology
- 4.2.7. Analysis by Target Indication
- 4.2.8. Analysis by Source Cell
- 4.2.9. Analysis by Application Area
- 4.2.10. Analysis by Additional Service(s) Offered
- 4.2.11. Analysis by Type of Offering
4.3. Cell Reprogramming Service and Product Providers: List of Non-Industry Players
- 4.3.1. Analysis by Geographical Location
- 4.3.2. Analysis by Type of Technology Used
- 4.3.3. Analysis by Source Cell for iPSC Generation
- 4.3.4. Analysis by Type of Offering
4.4. Cell Reprogramming: List of Affiliated Products Providers

5. COMPANY COMPETITIVENESS ANALYSIS

5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis: iPSC Generation Service and Product Providers
5.5. Competitiveness Analysis: Direct Reprogramming Service and Product Providers

6. COMPANY PROFILES

6.1. Chapter Overview
6.2. Allele Biotechnology
- 6.2.1. Company Overview
- 6.2.2. Recent Developments and Future Outlook
6.3. ALSTEM
- 6.3.1. Company Overview
- 6.3.2. Recent Developments and Future Outlook
6.4. Applied Biological Materials
- 6.4.1. Company Overview
- 6.4.2. Recent Developments and Future Outlook
6.5. Axol Bioscience
- 6.5.1. Company Overview
- 6.5.2. Recent Developments and Future Outlook
6.6. Creative Bioarray
- 6.6.1. Company Overview
  - 6.6.1.1. Recent Developments and Future Outlook
6.7. DefiniGEN
- 6.7.1. Company Overview
- 6.7.2. Recent Developments and Future Outlook
6.8. FUJIFILM Cellular Dynamics International
- 6.8.1. Company Overview
- 6.8.2. Recent Developments and Future Outlook
6.9. Lonza
- 6.9.1. Company Overview
- 6.9.2. Recent Developments and Future Outlook
6.10. Mogrify
- 6.10.1. Company Overview
- 6.10.2. Recent Developments and Future Outlook
6.11. REPROCELL
- 6.11.1. Company Overview
  - 6.11.1.1. Recent Developments and Future Outlook
6.12. Stemnovate
- 6.12.1. Company Overview
- 6.12.2. Recent Developments and Future Outlook
6.14. Thermo fisher Scientific
- 6.14.1. Company Overview
  - 6.14.1.1. Recent Developments and Future Outlook

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Stem Cell Therapies: Clinical Trial Analysis
- 7.3.1. Analysis by Trial Registration Year
- 7.3.2. Analysis by Trial Phase
- 7.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
- 7.3.4. Analysis by Study Design
- 7.3.5. Analysis by Trial Recruitment Status
- 7.3.6. Analysis by Sponsor / Collaborator
- 7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
- 7.3.8. Analysis by Trial Focus
- 7.3.9. Analysis by Type of Stem Cell
- 7.3.10. Analysis by Therapeutic Area
- 7.3.11. Analysis by Type of Stem Cell and Therapeutic Area
- 7.3.12. Geographical Analysis by Number of Clinical Trials
- 7.3.13. Geographical Analysis by Trial Recruitment Status
- 7.3.14. Geographical Analysis by Enrolled Patient Population

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Cell Reprogramming Services and Products Market: List of Partnerships and Collaborations
- 8.3.1. Analysis by Year of Partnership
- 8.3.2. Analysis by Type of Partnership
- 8.3.3. Analysis by Year of Partnership and Type of Partner
- 8.3.4. Analysis by Type of Partnership and Type of Partner
- 8.3.5. Analysis by Type of Stem Cell
- 8.3.6. Analysis by Target Therapeutic Area
- 8.3.7. Analysis by Application
- 8.3.8. Most Active Players: Analysis by Number of Partnerships
- 8.3.9. Regional Analysis
- 8.3.10. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNERSHIP OPPORTUNITIES

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Stem Cell Therapy Developers: Likely Partners for Cell Reprogramming Service and Product Providers
- 9.4.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
- 9.4.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
- 9.4.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
9.5. Stem Cell Therapy Contract Manufacturers: Likely Partners for Cell Reprogramming Service and Product Providers
- 9.5.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
- 9.5.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
- 9.5.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

10. MARKET FORECAST

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Forecast Methodology and Key Assumptions
10.4. Global Cell Reprogramming Services and Products Market, Till 2035
- 10.4.1. Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, Till 2035
  - 10.4.1.1. Cell Reprogramming Services and Products Market for Episomal Reprogramming, Till 2035
  - 10.4.1.2. Cell Reprogramming Services and Products Market for mRNA Reprogramming, Till 2035
  - 10.4.1.3. Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, Till 2035
  - 10.4.1.4. Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, Till 2035
- 10.4.2. Global Cell Reprogramming Services and Products Market: Distribution by Type of Source Cell, Till 2035
  - 10.4.2.1. Cell Reprogramming Services and Products Market for Fibroblasts, Till 2035
  - 10.4.2.2. Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, Till 2035
  - 10.4.2.3. Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, Till 2035
  - 10.4.2.4. Cell Reprogramming Services and Products Market for Other Cells, Till 2035
- 10.4.3. Global Cell Reprogramming Services and Products Market: Distribution by Type of Application, Till 2035
  - 10.4.3.1. Cell Reprogramming Services and Products Market for Research, Till 2035
  - 10.4.3.2. Cell Reprogramming Services and Products Market for Therapeutic, Till 2035
- 10.4.4. Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, Till 2035
  - 10.4.4.1. Cell Reprogramming Services and Products Market in North America, Till 2035
  - 10.4.4.2. Cell Reprogramming Services and Products Market in Europe, Till 2035
  - 10.4.4.3. Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, Till 2035

11. EXECUTIVE INSIGHTS

11.1. Chapter Overview
11.2. Company A
- 11.2.1. Company Snapshot
- 11.2.2. Interview Transcript: Co-Founder and Chief Executive Officer
11.3. Company B
- 11.3.1. Company Snapshot
- 11.3.2. Interview Transcript: Chief Scientific Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100193

List of Tables

Table 3.1 Differences between Stem Cell Therapies and Other Biologics
Table 4.1 Cell Reprogramming Services and Products: List of Industry Players
Table 4.2 Cell Reprogramming Services and Products: List of Non-Industry Players
Table 4.3 Cell Reprogramming Services and Products: List of Affiliated Product Providers
Table 6.1 Cell Reprogramming Service and Product Providers: List of Profiled Companies
Table 6.2 ALSTEM: Company Snapshot
Table 6.3 ALSTEM: Recent Developments and Future Outlook
Table 6.4 Applied Biological Materials: Company Snapshot
Table 6.5 Applied Biological Materials: Recent Developments and Future Outlook
Table 6.6 Axol Bioscience: Company Snapshot
Table 6.7 Axol Bioscience: Recent Developments and Future Outlook
Table 6.8 Creative Bioarray: Company Snapshot
Table 6.9 Creative Bioarray: Recent Developments and Future Outlook
Table 6.10 DefiniGEN: Company Snapshot
Table 6.11 DefiniGEN: Recent Developments and Future Outlook
Table 6.12 FUJIFILM Cellular Dynamics International: Company Snapshot
Table 6.13 FUJIFILM Cellular Dynamics International: Recent Developments and Future Outlook
Table 6.14 Lonza: Company Snapshot
Table 6.15 Lonza: Recent Developments and Future Outlook
Table 6.16 Mogrify: Company Snapshot
Table 6.17 Mogrify: Recent Developments and Future Outlook
Table 6.18 REPROCELL: Company Snapshot
Table 6.19 REPROCELL: Recent Developments and Future Outlook
Table 6.20 Stemnovate: Company Snapshot
Table 6.21 Stemnovate: Recent Developments and Future Outlook
Table 6.22 Thermo Fisher Scientific: Company Snapshot
Table 6.23 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Cell Reprogramming Services: List of Partnerships and Collaborations
Table 9.1 Likely Partners for Cell Reprogramming Service and Product Providers in North America
Table 9.2 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
Table 9.3 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
Table 9.4 Likely Partners for Cell Reprogramming Service and Product Providers in North America
Table 9.5 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
Table 9.6 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
Table 11.1 Asgard Therapeutics: Company Snapshot
Table 11.2 Phenocell: Company Snapshot
Table 13.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
Table 13.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
Table 13.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
Table 13.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
Table 13.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
Table 13.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
Table 13.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
Table 13.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
Table 13.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
Table 13.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
Table 13.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Source Cell for iPSC Generation and company size
Table 13.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
Table 13.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of directly reprogrammed cell
Table 13.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
Table 13.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Table 13.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
Table 13.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
Table 13.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
Table 13.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
Table 13.20 Clinical Trial Analysis: Distribution by Trial Status
Table 13.21 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since Pre-2010
Table 13.22 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.23 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Since 2011
Table 13.24 Clinical Trial Analysis: Distribution by Study Design
Table 13.25 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 13.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 13.27 Clinical Trial Analysis: Leading Industry Players
Table 13.28 Clinical Trial Analysis: Analysis by Type of Stem Cell
Table 13.29 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Table 13.30 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.31 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 13.32 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Table 13.33 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Table 13.34 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Table 13.35 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 13.36 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 13.37 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient
Table 13.38 Partnerships and Collaborations: Analysis by Year of Partnership
Table 13.39 Partnerships and Collaborations: Analysis by Type of Partnership
Table 13.40 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Table 13.41 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 13.42 Partnerships and Collaborations: Analysis by Type of Stem Cell
Table 13.43 Partnerships and Collaborations: Analysis by Target Therapeutic Area
Table 13.44 Partnerships and Collaborations: Analysis by Application
Table 13.45 Most Active Players: Distribution by Number of Partnerships
Table 13.46 Partnerships and Collaborations: Regional Analysis
Table 13.47 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.48 Global Cell Reprogramming Services and Products Market, Till 2035 (USD Million)
Table 13.49 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, Till 2035
Table 13.50 Cell Reprogramming Services and Products Market for Episomal Reprogramming, Till 2035 (USD Million)
Table 13.51 Cell Reprogramming Services and Products Market for mRNA Reprogramming, Till 2035 (USD Million)
Table 13.52 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, Till 2035 (USD Million)
Table 13.53 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, Till 2035 (USD Million)
Table 13.54 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, Till 2035
Table 13.55 Cell Reprogramming Services and Products Market for Fibroblasts, Till 2035 (USD Million)
Table 13.56 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, Till 2035 (USD Million)
Table 13.57 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, Till 2035 (USD Million)
Table 13.58 Cell Reprogramming Services and Products Market for Other Cells, Till 2035 (USD Million)
Table 13.59 Global Cell Reprogramming Services and Products Market: Distribution by Application, Till 2035
Table 13.60 Cell Reprogramming Services and Products Market for Research, Till 2035 (USD Million)
Table 13.61 Cell Reprogramming Services and Products Market for Therapeutic Use, Till 2035 (USD Million)
Table 13.62 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, Till 2035
Table 13.63 Cell Reprogramming Services and Products Market in North America, Till 2035 (USD Million)
Table 13.64 Cell Reprogramming Services and Products Market in Europe, Till 2035 (USD Million)
Table 13.65 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)

List of Figures

Figure 3.1 Cellular Lineages used for Isolation of Stem Cells
Figure 3.2 Steps Involved in the Development and Administration of Stem Cells
Figure 3.3 Classification of Stem Cells
Figure 3.4 Classification based on Source of Stem Cell
Figure 3.5 Differences between Allogeneic and Autologous Stem Cell Therapies
Figure 3.6 Classification of Stem Cells based on Origin
Figure 3.7 Classification of Adult Stem Cells
Figure 3.8 Classification based on Potency of Stem Cell
Figure 3.9 Key Application Areas for Stem Cell Therapies
Figure 3.10 Potential Applications of Cell Reprogramming
Figure 3.11 Key Growth Drivers and Constraints to Cell Reprogramming
Figure 4.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
Figure 4.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
Figure 4.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 4.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
Figure 4.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
Figure 4.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
Figure 4.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
Figure 4.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
Figure 4.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
Figure 4.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation and Company size
Figure 4.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
Figure 4.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Directly Reprogrammed cells
Figure 4.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
Figure 4.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
Figure 4.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
Figure 4.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
Figure 4.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
Figure 4.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
Figure 5.1 Competitiveness Analysis of iPSCs Generation Service and Product Providers
Figure 5.2 Competitiveness Analysis of Direct Reprogramming Service and Product Providers
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since Pre-2010
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Trial Registration Year, Since 2011
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.9 Clinical Trial Analysis: Leading Industry Players
Figure 7.10 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
Figure 7.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 7.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Stem Cell
Figure 8.6 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution by Application
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Regional Analysis
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreement
Figure 10.1 Global Cell Reprogramming Services and Products Market, Till 2035 (USD Million)
Figure 10.2 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, Till 2035
Figure 10.3 Cell Reprogramming Services and Products Market for Episomal Reprogramming, Till 2035 (USD Million)
Figure 10.4 Cell Reprogramming Services and Products Market for mRNA Reprogramming, Till 2035 (USD Million)
Figure 10.5 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, Till 2035 (USD Million)
Figure 10.6 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, Till 2035 (USD Million)
Figure 10.7 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, Till 2035
Figure 10.8 Cell Reprogramming Services and Products Market for Fibroblasts, Till 2035 (USD Million)
Figure 10.9 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, Till 2035 (USD Million)
Figure 10.10 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, Till 2035 (USD Million)
Figure 10.11 Cell Reprogramming Services and Products Market for Other Cells, Till 2035 (USD Million)
Figure 10.12 Global Cell Reprogramming Services and Products Market: Distribution by Application, Till 2035
Figure 10.13 Cell Reprogramming Services and Products Market for Research, Till 2035 (USD Million)
Figure 10.14 Cell Reprogramming Services and Products Market for Therapeutic Use, Till 2035 (USD Million)
Figure 10.15 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, Till 2035
Figure 10.16 Cell Reprogramming Services and Products Market in North America, Till 2035 (USD Million)
Figure 10.17 Cell Reprogramming Services and Products Market in Europe, Till 2035 (USD Million)
Figure 10.18 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)

Cell Reprogramming Market: Industry Trends and Global Forecasts - Distribution by Type of Technology, Type of Source Cell, Type of Application and Key Geographical Regions

Description

Table of Contents

List of Tables

GLOBAL CELL REPROGRAMMING MARKET: OVERVIEW

GLOBAL CELL REPROGRAMMING MARKET: GROWTH AND TRENDS

GLOBAL CELL REPROGRAMMING MARKET: KEY INSIGHTS

Example Players in the Cell Reprogramming Market

GLOBAL CELL REPROGRAMMING MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. CURRENT MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT

8. PARTNERSHIPS AND COLLABORATIONS

9. LIKELY PARTNERSHIP OPPORTUNITIES

10. MARKET FORECAST

11. EXECUTIVE INSIGHTS

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures